Pharmaceuticals

The Readout LOUD Elaine Chen, Allison DeAngelis, and Adam Feuerstein

The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children

Pharma Matthew Herper

STAT Plus: Pfizer’s blockbuster Ibrance slows tumor progression in another type of breast cancer

Pharmalot Ed Silverman

STAT Plus: Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds

Pharmalot Ed Silverman

STAT Plus: Wall Street wags say a bill to force insurers or PBMs to sell pharmacies has low odds

Pharma Jason Mast

Gilead to test once-a-year HIV prevention shot

Pharma Elaine Chen and Katie Palmer

STAT Plus: Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s

Pharmalot Ed Silverman

STAT Plus: Ohio court sides with CVS, Walmart, and Walgreens in opioid case

D.C. Diagnosis Sarah Owermohle

STAT Plus: Budget negotiations heat up as ACA subsidy extension, BIOSECURE get dropped

Health Angus Chen, Adam Feuerstein, Jonathan Wosen, and Meghana Keshavan

STAT Plus: Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma

Exclusive Rachel Cohrs Zhang and John Wilkerson

STAT Plus: The pharma industry isn’t lobbying against RFK Jr.’s nomination for a top health role

Health Angus Chen

STAT Plus: Early treatment may delay or prevent multiple myeloma in high-risk patients, according to new study

Pharma Andrew Joseph

STAT Plus: GSK myeloma medicine improves survival in trial, another step in the drug’s revival

Health Adam Feuerstein, Jonathan Wosen, Angus Chen, and Meghana Keshavan

STAT Plus: Biopharma leaders lay out vision for the future of blood cancer treatment

Politics John Wilkerson

STAT Plus: BIOSECURE Act, aimed at Chinese drug manufacturers, is dealt a major blow

Pharmalot Ed Silverman

STAT Plus: European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Health Andrew Joseph

STAT Plus: U.K. to restrict Eli Lilly’s obesity drug to patients with greatest need 

Pharmalot Ed Silverman

STAT Plus: U.S. Patent Office pulls controversial rule to curb pharma patent abuse

Biotech Andrew Joseph

STAT Plus: Novartis to pay $1 billion upfront to license Huntington’s drug from PTC

Pharmalot Ed Silverman

STAT Plus: Big restaurant chains get an ‘F’ for antibiotic use in their meat supplies

Pharmalot Ed Silverman

STAT Plus: Bristol Myers is the latest drug company to sue HHS over payment terms for 340B hospitals

Politics John Wilkerson

STAT Plus: It might be now or never for the BIOSECURE Act

Health Lizzy Lawrence

STAT Plus: Trump taps biotech investor Jim O’Neill for HHS deputy secretary

Health Rachel Cohrs Zhang

STAT Plus: Trump picks Stanford’s Jay Bhattacharya to lead NIH

Politics Rachel Cohrs Zhang

STAT Plus: Medicare moves to expand coverage for weight loss drugs Wegovy, Zepbound

First Opinion David Balto

STAT Plus: Don’t expect Novo-Catalent merger investigation to fizzle out under the new Trump administration

Pharma Andrew Joseph

STAT Plus: Roche immunotherapy fails in lung cancer study, raising questions about drug’s target

Pharmalot Ed Silverman

STAT Plus: Minnesota becomes first state to release report on 340B drug discount program for ‘safety-net’ hospitals

Biotech Allison DeAngelis, Adam Feuerstein, Matthew Herper, Lizzy Lawrence, Nicholas St. Fleur, and Jonathan Wosen

STAT Plus: ‘We dodged a bullet’: Biotech and pharma react to selection of Marty Makary for FDA commissioner